Sigma Healthcare (ASX: SIG) - Investment Research Report

3-Year / 5-Year Price Scenarios

Base EPS: $0.12 — Analyst normalised starting EPS of A$0.12 is a judgmental bridge from FY25 statutory EPS of A$0.051: FY25 is a reverse-acquisition period with only partial Sigma contribution and merger costs. It is not reported company guidance.

0. Information Richness & AI Limitations

Grade B. Sigma has a freshly audited post-merger annual report and current ASX quote, but FY25 is a reverse-acquisition presentation: Chemist Warehouse is shown for the full year while acquired Sigma contributes only from 12 February 2025. The evidence base is therefore strong on reported facts but weaker on steady-state earnings. Confidence in the business description is higher than confidence in the 3-year and 5-year price scenarios.

1. Data & Cross-Validation

The ASX company header returned A$2.945 and market capitalisation of A$34.169 billion on 31 July 2026. The implied current share count is approximately 11,603.5 million (market cap / price), which is used for the market-cap arithmetic; FY25 audited diluted weighted-average shares were 10,485.006 million because the merger changed the equity structure during the year. Sigma's FY25 Annual Report reports revenue of A$6,001.835m, NPAT attributable to owners of A$529.914m, diluted EPS of 5.1 cents and a 1.3-cent final dividend. Statutory EBIT was A$767.883m, normalised EBIT A$834.527m, operating cash flow A$598.8m and net debt A$752.2m. The official financial-fundamentals snapshot independently displayed approximately A$6,001.84m revenue, A$806.43m EBIT and A$571.71m net income; the EBIT and net-income definitions differ from audited statutory measures, so the annual report is preferred. The ASX header is the independent live market-data source.

2. Business Essence - Duan Yongping

One line: Sigma combines Chemist Warehouse's high-volume pharmacy franchise and retail brand with Sigma's pharmaceutical wholesale and distribution infrastructure. Customers receive low prices, broad product availability and local pharmacy service; franchisees receive a recognised brand, procurement scale, logistics and marketing. Revenue is partly recurring through wholesale and franchise relationships, while operating leverage comes from volume, distribution density, own-label products and merger synergies. The key limitation is that pharmacy reimbursement, supplier terms and competition constrain pricing power.

3. Moat - Buffett

The moat is a combination of brand, purchasing scale, pharmacy footprint, supply-chain assets and franchise density. Chemist Warehouse had 967 stores globally at FY25 year-end and the group franchised 881 Australian stores across its banners. Sigma distributed approximately 530 million units annualised through 14 distribution centres with delivery-in-full above 99.5%. These assets and relationships are difficult to reproduce quickly, and scale supports low prices and supplier relevance. The moat is potentially widening through integration and own-label products, but the merger also creates execution risk and franchisees can switch if economics weaken.

4. Reverse Thinking & Risks - Munger

The central inversion is that a great retail brand does not automatically create great shareholder returns if the purchase price capitalises peak growth. FY25's 32% EBIT increase and 11% Chemist Warehouse like-for-like growth are encouraging, but FY25 comparatives are not like-for-like because of the reverse acquisition. Disconfirming evidence would be weak post-merger cash conversion, falling franchisee economics or repeated guidance/synergy delays.

5. Management - Duan Yongping + Buffett

Management completed the Chemist Warehouse merger, upgraded the synergy target from A$60m to A$100m annually within four years and reported net debt below the A$1.0-A$1.3bn merger-prospectus starting range. That is constructive evidence on execution and capital discipline. The annual report also discloses A$46.6m merger costs, A$12.7m integration costs and A$7.3m purchase-price-accounting charges, making normalisation transparent. The test for management is now delivery: convert scale into cash, reduce debt and maintain franchisee trust without over-expanding internationally.

6. Industry & Civilizational Trend - Li Lu

Healthcare and medicines are essential, but pharmacy retail is not immune to technological or regulatory change. An ageing population, chronic-care demand and consumer value-seeking support the addressable market; e-commerce, online fulfilment, pharmacist labour constraints and government medicine pricing shape the industry structure. Sigma sits at the intersection of wholesale infrastructure and consumer pharmacy distribution. The long-run opportunity is a scaled, data-enabled healthcare platform; the ceiling is set by regulation and the finite economics of physical stores.

7. Valuation & Scenarios - Buffett + Duan

The reported FY25 EPS of A$0.051 is not a clean steady-state denominator because the accounting period includes the reverse acquisition and merger costs. I therefore use an explicit analyst normalised starting EPS of A$0.12, not company guidance. On that base, the 3-year bull/base/bear targets are A$5.47/A$3.19/A$1.59 at 25%/50%/25% probabilities, producing a weighted A$3.36 or +14.1% before dividends. The 5-year targets are A$6.04/A$3.10/A$1.41, producing a weighted A$3.41 or +15.8%. These outcomes are highly sensitive to the normalised EPS bridge, synergy timing and terminal P/E. A high current P/E on statutory FY25 EPS is a warning that the market is already underwriting significant earnings normalisation; the margin of safety is therefore more compelling below A$2.70.

8. Decision Memo

Decision: watch / build only at a margin of safety. The business quality is attractive, but the post-merger earnings base remains unproven and the current valuation depends on successful integration. Buy zone: A$2.35-A$2.70. Add when audited earnings show at least A$0.15 EPS, cash conversion remains strong and net debt declines while synergies are delivered. Sell or reassess if synergy delivery slips, franchisee economics deteriorate, leverage rises or regulatory change compresses margins. The thesis is invalidated by evidence that scale is not translating into durable per-share cash earnings.

Four-Master Commentary

Buffett (analytical simulation, not a real quotation): The combination has a strong brand and distribution scale, but I would wait for a clean earnings record before paying a premium.

Munger (analytical simulation, not a real quotation): Invert the merger: if synergies fail and working capital absorbs cash, the apparent growth can become an expensive accounting story.

Duan Yongping (analytical simulation, not a real quotation): A good consumer-health franchise is valuable when franchisees and customers both win; insist on a reasonable price and simple evidence of repeat economics.

Li Lu (analytical simulation, not a real quotation): Essential healthcare demand and logistics scale are durable, while regulation and technology determine how much of the value chain Sigma can retain.